BECN1 and neoplasm: For example, low expression of Beclin 1 associated with poor prognosis in breast cancer [19, 20], ovarian cancer [21], lung cancer [22], hepatocellular carcinoma [23], cholangiocarcinoma [24], pancreatic cancer [25], hypopharyngeal cancer [26], laryngeal cancer [27], esophageal cancer [28], duodenal cancer [29], gastric cancer [30], lymphomas [31–33], etc. High expression of Beclin 1 connected to tumor aggressiveness in nasopharyngeal carcinoma [34], endometrial cancer [35], and colorectal cancer [36].